Abstract 1609
Background
Concurrent chemoradiotherapy (CRT) with single agent cisplatin for patients with head and neck cancers (HNC) have been used as the standard treatment for a long time. Although recommended dose of cisplatin is 100mg/m2, we sometimes reduced cisplatin dose to 80mg/m2 depends on general condition in real world setting. It remains unclear whether the efficacy and the safety, especially in nephrotoxicity, for CRT of HNC patients with cisplatin dose 100mg/m2 or 80mg/m2 are different.
Methods
We reviewed medical records of NHC patients who received CRT in our institute retrospectively. The primary objectives of this study were to evaluate the nephrotoxicity and the rate of patients treated with cumulative dose of cisplatin 200mg/m2 or more.
Results
During January 2014 to October 2017, 261 HNC patients who received CRT were treated. The starting dose of cisplatin were 80mg/m2 in 118 patients vs 100mg/m2 in 143 patients, respectively. There were more patients over 70 years who received cisplatin in 80mg/m2 than 100mg/m2 (27.1% vs 4.2%, p < 0.001). The mean Creatinine Clearance (Ccr) obtained using the Cockcroft-Gaut at baseline was significantly lower in 80mg/m2 than 100mg/m2 (87.82 vs 97.28, p = 0.0022). There were no significantly differences in patient’s other characteristics as follows gender, performance states, pathology. The incidence of Grade 2 or higher elevation in creatinine was 2 (1.7%) in 80mg/m2 group and 4 (2.8%) in 100mg/m2 group, respectively (p = 0.554). The rate of change in CCR showed no difference between both groups (-5.73% in 80mg/m2 vs -7.63% in 100mg/m2, p = 0.2927), either. The rate of cumulative dose of cisplatin ≧200mg/m2 was significantly higher in 100mg/m2 than 80mg/m2 (97.2% vs 72.0%, p < 0.001). 2-year PFS rate was not significantly different between 80 mg/m2and 100 mg/m2 in oropharynx (89.3% vs 88.2%, p = 0.7760) and in hypopharynx/ larynx (70.28% vs 80.92%, p = 0.4740), respectively.
Conclusions
Cisplatin dose of CRT for HNC patients in 100mg/m2was feasible without increasing the nephrotoxicity and the rate of cumulative dose of cisplatin ≧ 200mg/m2was higher compared to 80mg/m2.
Clinical trial identification
The study protocol was approved by the local institutional review board (approval no. 2017-1197) and conducted in accordance with the provisions of the Declaration of Helsinki and local regulations.
Legal entity responsible for the study
Tomoyo Oguri.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract